Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Chief Scientific Officer | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 1,738 · Balance 0 F1: The shares sold were previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") for the purchase period of January 1, 2026 through June 30, 2026 in a transaction that was exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares sold were previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") for the purchase period of January 1, 2026 through June 30, 2026 in a transaction that was exempt under Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 20, 2026 00:46 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | SaleCommon Stock | 1,738 | $4.76 | $8,272.88 |
DisclosureSEC source: 0001628280-26-058107 · wk-form4_1787186763.xml · nonDerivative · entry 1 Tardiff Daniel · CIK 0002089301 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The shares sold were previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") for the purchase period of January 1, 2026 through June 30, 2026 in a transaction that was exempt under Rule 16b-3(c). Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:48 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0002089301-26-000003 · wk-form4_1775249299.xml · derivative · entry 1 Tardiff Daniel · CIK 0002089301 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. Read SEC document |
| December 11, 2025 Filed Dec 22, 2025 22:42 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 145,500 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0002089301-25-000004 · wk-form4_1766443325.xml · derivative · entry 1 Tardiff Daniel · CIK 0002089301 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,500 Underlying: Common Stock · 145,500 shares Expires 2035-12-10 F1 · derivative.exercise_date: This option has a vesting start date of December 1, 2025 and vests as to one third (33.33%) of the shares subject to the option on the first anniversary of the vesting start date and as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.